Vyant Bio Announces 77,522 Votes Needed to Approve Sale of
CHERRY HILL, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (OTC: VYNT), today announced that its special meeting of...
Stay updated with breaking news from Stemonix Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
CHERRY HILL, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (OTC: VYNT), today announced that its special meeting of...
Cherry Hill, N.J. and Esch-sur-Alzette, Luxembourg, March 29, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), an...
Cherry Hill, N.J. and Esch-sur-Alzette, Luxembourg, March 29, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental
/PRNewswire/ -- As per the report published by The Brainy Insights, the global computational biology market is expected to grow from USD 2.96 billion in 2020...
Vyant Bio Announces Investor Webcast to Provide Updates Post Merger between Cancer Genetics and StemoniX CHERRY HILL, N.J., April 01, 2021 (GLOBE NEWSWIRE) — Vyant Bio, Inc. (the “Company”) (Nasdaq: VYNT), is a new force in drug discovery focused on integrating human-powered scientific and technology-based systems to de-risk and accelerate the discovery and development of therapeutics for biopharma partners as well as for the proprietary pipeline of the Company. Today, Vyant Bio announced that an investor webcast will be hosted on Tuesday, April 6, 2021. Jay Roberts, Chief Executive Off...